Advanced Search

Study Preview



Study Title and Description

Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans.



Key Questions Addressed
1 Is this a fiber intervention study?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans.
Author Bouhnik Y., Vahedi K., Achour L., Attar A., Salfati J., Pochart P., Marteau P., Flourié B., Bornet F., Rambaud JC.
Country INSERM U 290, Fonctions intestinales, métabolisme et nutrition, Hôpital Saint-Lazare, 75010 Paris, France.
Year 1999
Numbers Pubmed ID: 9915885

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Fiber Database
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
Year of Publication 1999
  • Comments Comments (
    0
    ) |
Country of Publication France
  • Comments Comments (
    0
    ) |
What was the study design? Randomized Controlled Trial (parallel)
  • Comments Comments (
    0
    ) |
Was the study blinded? unspecified
  • Comments Comments (
    0
    ) |
Study diet type Unspecified
  • Comments Comments (
    0
    ) |
Level of feeding control for dietary intervention Food partially provided
  • Comments Comments (
    0
    ) |
Sample size 40
  • Comments Comments (
    0
    ) |
Is there a run-in period? No
  • Comments Comments (
    0
    ) |
Is there a washout period? Not applicable
  • Comments Comments (
    0
    ) |
Did the administered fiber dose change over the course of the study? No
  • Comments Comments (
    0
    ) |
What is the age of the population (categorical)? Adults (20+ Years)
  • Comments Comments (
    0
    ) |
Study population, mean age in years 29.6
  • Comments Comments (
    0
    ) |
Study population, age range in years 18-47
  • Comments Comments (
    0
    ) |
Study Population, mean BMI, kg/m2 NR
  • Comments Comments (
    0
    ) |
Study population, BMI Range, kg/m2 -
  • Comments Comments (
    0
    ) |
Baseline health status Healthy
  • Comments Comments (
    0
    ) |
Gender (% male) 45
  • Comments Comments (
    0
    ) |
Fiber 1-type Fructooligosaccharide
  • Comments Comments (
    0
    ) |
Fiber 1-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 1-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 1- dose 1 (g) 2.5
  • Comments Comments (
    0
    ) |
Fiber 1- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 1-Duration of intervention 7 days
  • Comments Comments (
    0
    ) |
Fiber 1-how was the fiber administered? Powder
  • Comments Comments (
    0
    ) |
Fiber 2-type Fructooligosaccharide
  • Comments Comments (
    0
    ) |
Fiber 2-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 2-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 2- dose 1 (g) 5
  • Comments Comments (
    0
    ) |
Fiber 2- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 2-Duration of intervention 7 days
  • Comments Comments (
    0
    ) |
Fiber 2-how was the fiber administered? Powder
  • Comments Comments (
    0
    ) |
Fiber 3-type Fructooligosaccharide
  • Comments Comments (
    0
    ) |
Fiber 3-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 3-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 3- dose 1 (g) 10
  • Comments Comments (
    0
    ) |
Fiber 3- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 3-Duration of intervention 7 days
  • Comments Comments (
    0
    ) |
Fiber 3-how was the fiber administered? Powder
  • Comments Comments (
    0
    ) |
Fiber 4-type Fructooligosaccharide
  • Comments Comments (
    0
    ) |
Fiber 4-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 4-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 4- dose 1 (g) 20
  • Comments Comments (
    0
    ) |
Fiber 4- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 4-Duration of intervention 7 days
  • Comments Comments (
    0
    ) |
Fiber 4-how was the fiber administered? Powder
  • Comments Comments (
    0
    ) |
Comparator 1- what was the comparator used in the intervention? saccharose powder, 20 g
  • Comments Comments (
    0
    ) |
Comparator 1-dose 0
  • Comments Comments (
    0
    ) |
Comparator 1-duration of comparator intervention 7 days
  • Comments Comments (
    0
    ) |
Comparator 1-how was the comparator administered to participants? Powder
  • Comments Comments (
    0
    ) |
Comparator 2- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 2-dose -
  • Comments Comments (
    0
    ) |
Comparator 2-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 2-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |
Comparator 3- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 3-dose -
  • Comments Comments (
    0
    ) |
Comparator 3-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 3-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |
Comparator 4- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 4-dose -
  • Comments Comments (
    0
    ) |
Comparator 4-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 4-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |


Baseline Characteristics
No baseline characteristics have been defined for this extraction form.



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Comments

Quality Dimensions
No quality dimensions were specified.

Quality Rating
No quality rating data was found.